[CAS NO. 1357302-64-7] OG-L002
PRODUCTS SPECIFICATIONS [1357302-64-7]
DESCRIPTION [1357302-64-7]
Overview
| MDL | MFCD27997969 |
|---|---|
| Molecular Weight | 225.29 |
| Molecular Formula | C15H15NO |
| SMILES | OC1=CC(C2=CC=C([C@@H]3[C@@H](N)C3)C=C2)=CC=C1 |
1 Publications Citing Use of MCE
Summary
IC50 & Target
IC50: 0.02 μM (LSD1), 1.38 μM (MAO-A), 0.72 μM (MAO-B), HSV IE [1]
In Vitro
OG-L002 inhibits viral IE gene expression in both cells with a significantly reduced IC 50 (IC 50 : ~10 µM in HeLa cells; IC 50 : ~3 µM in HFF cells) relative to the control MAOI TCP (IC 50 : ~1 mM) [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
OG-L002 (i.p.; 6-40 mg/kg; daily; for 7 days) reduces the levels of detectable viral genomes in the ganglia in a dose-dependent manner at both 3 and 5 days postinfection [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | 4-week-old BALB/c female mice [1] |
| Dosage: | 6, 20, 40 mg/kg |
| Administration: | Intraperitoneal; daily; for 7 days |
| Result: | Reduced the levels of detectable viral genomes in the ganglia in a dose-dependent manner at both 3 and 5 days postinfection. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 250 mg/mL ( 1109.68 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.4387 mL | 22.1936 mL | 44.3872 mL |
| 5 mM | 0.8877 mL | 4.4387 mL | 8.8774 mL |
| 10 mM | 0.4439 mL | 2.2194 mL | 4.4387 mL |